| Entry |
|
|---|
| Name |
Theophylline (JP18);
Elixophyllin (TN);
Quibron-t (TN);
Theo-24 (TN);
Theodur G (TN);
Theolair (TN);
Uniphyl (TN) |
|---|
| Product |
|
|---|
| Generic |
ELIXOPHYLLIN (Nostrum Laboratories), THEO-24 (Endo Pharmaceuticals), THEOPHYLLINE (Alembic Pharmaceuticals Limited), THEOPHYLLINE (Alembic Pharmaceuticals), THEOPHYLLINE (Amneal Pharmaceuticals NY LLC), THEOPHYLLINE (AvKARE), THEOPHYLLINE (Bionpharma Inc.,), THEOPHYLLINE (Bryant Ranch Prepack), THEOPHYLLINE (Camber Pharmaceuticals), THEOPHYLLINE (Chartwell RX), THEOPHYLLINE (Chartwell RX), THEOPHYLLINE (Glenmark Pharmaceuticals), THEOPHYLLINE (Glenmark Pharmaceuticals), THEOPHYLLINE (Golden State Medical Supply), THEOPHYLLINE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals), THEOPHYLLINE (Leading Pharma), THEOPHYLLINE (Nostrum Laboratories), THEOPHYLLINE (Nostrum Laboratories), THEOPHYLLINE (PAI Holdings), THEOPHYLLINE (Rhodes Pharmaceuticals L.P.), THEOPHYLLINE (Rhodes Pharmaceuticals), THEOPHYLLINE (Teva Pharmaceuticals), THEOPHYLLINE (Tris Pharma) |
|---|
| Formula |
C7H8N4O2
|
|---|
| Exact mass |
180.0647
|
|---|
| Mol weight |
180.164
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Respiratory system agent
DG01616 Xanthine derivative
DG01609 Xanthine-type bronchodilator
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
|
|---|
| Remark |
| Therapeutic category: | 2251 |
| Product (DG01061): | D00371<JP/US> |
|
|---|
| Efficacy |
Bronchodilator, Phosphodiesterase inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Xanthine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03DA Xanthines
R03DA04 Theophylline
D00371 Theophylline (JP18) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Phosphodiesterase Inhibitors, Airways Disease
Theophylline
D00371 Theophylline (JP18)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
225 Bronchodilators
2251 Xanthines
D00371 Theophylline (JP18)
Classification of Japanese OTC drugs [BR:br08313]
Agents for respiratory organs
26 Antitussives and expectorants
D00371 Theophylline (JP18)
Risk category of Japanese OTC drugs [BR:br08312]
First-class OTC drugs
Inorganic and organic chemicals
Theophylline
D00371 Theophylline (JP18)
Drug groups [BR:br08330]
Respiratory system agent
DG01616 Xanthine derivative
DG01609 Xanthine-type bronchodilator
DG01061 Theophylline
D00371 Theophylline
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01061 Theophylline
D00371 Theophylline
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adenosine
ADORA1
D00371 Theophylline (JP18) <JP/US>
ADORA2B
D00371 Theophylline (JP18) <JP/US>
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE
D00371 Theophylline (JP18) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00371 Theophylline
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00371
Drug groups [BR:br08330]
Respiratory system agent
DG01616 Xanthine derivative
DG01609 Xanthine-type bronchodilator
DG01061 Theophylline
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01061 Theophylline
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 13
1 C8y C 24.1848 -17.2082
2 C8y C 24.1848 -18.6318
3 C8y C 25.3867 -16.5023
4 N4x N 22.8837 -16.7764
5 N4y N 25.3867 -19.3144
6 N5x N 22.8837 -19.0636
7 N4y N 26.6061 -17.2374
8 O5x O 25.3867 -15.1253
9 C8x C 22.0669 -17.9317
10 C8y C 26.6061 -18.5794
11 C1a C 25.3867 -20.7440
12 C1a C 27.8547 -16.5606
13 O5x O 27.8547 -19.2794
BOND 14
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 3 8 2
8 4 9 1
9 5 10 1
10 5 11 1
11 7 12 1
12 10 13 2
13 6 9 2
14 7 10 1
|
|---|
